Literature DB >> 20018503

HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer.

Yi Luo1, Hitoshi Ohmori, Kiyomu Fujii, Yukiko Moriwaka, Tomonori Sasahira, Miyako Kurihara, Naokuni Tatsumoto, Takamitsu Sasaki, Yuichi Yamashita, Hiroki Kuniyasu.   

Abstract

High mobility group box (HMGB) 1 induces apoptosis of monocyte-lineage cells. We examined the effect of HMGB1 on Kupffer cells (KCs). In 50 Dukes C and 12 liver-metastasised Dukes D colorectal cancers (CRCs), higher HMGB1 concentration in the primary tumours and metastatic foci, and fewer KCs were found in Dukes D cases than in Dukes C cases. The portal blood HMGB1 concentration was higher in Dukes D cases than in Dukes C cases. HMGB1 induced growth inhibition and apoptosis in mouse KCs in a dose-dependent manner, which was associated with the phosphorylation of c-Jun N-terminal kinase (JNK). JNK inhibition and knockdown of HMGB1 receptor abrogated growth inhibition and apoptosis. In a nude mouse liver metastasis model, the caecal administration of HMGB1 decreased the number of KCs and increased the embedment of Colo320 CRC cells in a dose-dependent manner. HMGB1 transfection increased the liver metastasis of Colo320 cells, and the metastasis was inhibited by anti-HMGB1 antibody administration. These results suggest that HMGB1 secreted from primary tumours decreases the number of KCs and attenuates the anti-metastatic defence of the liver in patients with CRCs. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018503     DOI: 10.1016/j.ejca.2009.11.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.

Authors:  Liguo Lin; Kaihua Zhong; Zhongkai Sun; Guozhong Wu; Guodong Ding
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

Review 2.  Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance.

Authors:  Konstantinos A Paschos; Ali W Majeed; Nigel C Bird
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

3.  Kupffer Cell Metabolism and Function.

Authors:  Anh Thu Nguyen-Lefebvre; Anatolij Horuzsko
Journal:  J Enzymol Metab       Date:  2015-08-14

Review 4.  HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.

Authors:  Kim Jun Cheng; Mohammed Abdullah Alshawsh; Elsa Haniffah Mejia Mohamed; Surendran Thavagnanam; Ajantha Sinniah; Zaridatul Aini Ibrahim
Journal:  Cell Oncol (Dordr)       Date:  2019-11-01       Impact factor: 6.730

5.  Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.

Authors:  Rui-Qing Peng; Xiao-Jun Wu; Ya Ding; Chun-Yan Li; Xing-Juan Yu; Xing Zhang; Zhi-Zhong Pan; De-Sen Wan; Li-Ming Zheng; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

6.  Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma.

Authors:  Lingyin Zhu; Lin Ren; Yingxuan Chen; Jingyuan Fang; Zhizheng Ge; Xiaobo Li
Journal:  J Cell Mol Med       Date:  2015-06-23       Impact factor: 5.310

Review 7.  Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.

Authors:  Christin Pilzweger; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2015-06-16

8.  Increased HMGB1 expression correlates with higher expression of c-IAP2 and pERK in colorectal cancer.

Authors:  Wenjia Zhang; Fangmei An; Min Xia; Qiang Zhan; Wenying Tian; Yang Jiao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

Review 9.  The dual role and therapeutic potential of high-mobility group box 1 in cancer.

Authors:  Si-Jia He; Jin Cheng; Xiao Feng; Yang Yu; Ling Tian; Qian Huang
Journal:  Oncotarget       Date:  2017-05-16

10.  Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases.

Authors:  David P J van Dijk; Matthew Krill; Farshad Farshidfar; Ting Li; Sander S Rensen; Steven W M Olde Damink; Elijah Dixon; Francis R Sutherland; Chad G Ball; Vera C Mazurak; Vickie E Baracos; Oliver F Bathe
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-10-31       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.